Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 15/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2879355 | 1.00 | MLNR (1.00) | MLNRABL1FFAR4NR3C1GHSR | |
| SCHEMBL1999285 | 0.90 | MLNR (1.00) | MLNRGHSR | |
| SCHEMBL1997887 | 0.85 | MLNR (0.82) | MLNRCYP3A4 | |
| SCHEMBL2851975 | 0.85 | MLNR (0.74) | MLNRABL1FFAR4NR3C1CYP3A4 | |
| SCHEMBL2003109 | 0.82 | MLNR (0.69) | MLNRABL1NR3C1BCRMKNK1 | |
| SCHEMBL2003110 | 0.78 | MLNR (0.63) | MLNRABL1FFAR4NR3C1CYP3A4 | |
| SCHEMBL2004331 | 0.76 | MLNR (1.00) | MLNRGHSRCYP3A4 | |
| SCHEMBL1999746 | 0.76 | MLNR (1.00) | MLNRGHSRCYP3A4 | |
| SCHEMBL2849453 | 0.74 | MLNR (0.73) | MLNR | |
| SCHEMBL1999589 | 0.74 | MLNR (0.63) | MLNRFFAR4GHSRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964597-B2 | Piperazinyl-sulfonamide derivatives useful in the treatment of GPR38 receptor mediated diseases | GLAXO GROUP LIMITED (GB) | 2011-06-21 | — | — | US | claimed |
| US-20100256364-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LTD. | 2010-10-07 | — | — | US | claimed |
| US-7964597-B2 | Piperazinyl-sulfonamide derivatives useful in the treatment of GPR38 receptor mediated diseases | GLAXO GROUP LIMITED (GB) | 2011-06-21 | — | — | US | disclosed |
| US-7964597-B2 | Piperazinyl-sulfonamide derivatives useful in the treatment of GPR38 receptor mediated diseases | GLAXO GROUP LIMITED (GB) | 2011-06-21 | — | — | US | disclosed |
| US-7964597-B2 | Piperazinyl-sulfonamide derivatives useful in the treatment of GPR38 receptor mediated diseases | GLAXO GROUP LIMITED (GB) | 2011-06-21 | — | — | US | disclosed |
| US-20100256364-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LTD. | 2010-10-07 | — | — | US | disclosed |
| US-20100256364-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LTD. | 2010-10-07 | — | — | US | disclosed |
| US-20100256364-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LTD. | 2010-10-07 | — | — | US | disclosed |
| WO-2009068552-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256364-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GPR68, GPR88, GIPR | MLNR 12/4885ABL1 3422/4885FFAR4 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.